N/A N=150 Project to Improve Communication About Serious Illness - Pilot Study
Malignant Neoplasm · Leukemia, Lymphocytic, Chronic, B-Cell · Lung Disease Chronic
Primary: Documentation of Goals of Care — 16; 6 Participants — p=0.036
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients
HIV-infection
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
Phase 3 N=172 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
Pulmonary Arterial Hypertension
Primary: Time to First Confirmed Morbidity or Mortality Event — NA; 9.6 Months
Phase 1 N=446 Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Locally Advanced and Metastatic Solid Tumors
Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 1; 3; 6; 15 Participants
Phase 1 N=81 Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
RSV Infection
Primary: Frequency of Grade 1 or Higher Solicited Adverse Events (AEs) by Grade — 14; 7; 27; 11 Participants
N/A N=40 Clinical Evaluation of Two Toric Soft Contact Lenses
Astigmatism
Primary: Overall Fit Acceptance — 3.6; 3.7 units on a scale
N/A N=15 Post-stroke Pain taVNS
Stroke · Pain
Primary: Thermal Pain Threshold — 41.84; 42.51 Celsius
Phase 2 N=53 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 — -0.58; -1.03 Score on a scale — p==0.224
Phase 2 N=33 A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Frontotemporal Dementia
Primary: Severity of TEAEs — 43; 58; 84; 4 TEAEs (all)
N/A N=8 Safety and Feasibility of tDCS to Enhance Auditory Rehabilitation in Cochlear Implant Recipients
Hearing Loss
Primary: Number Eligible Patients Who Expressed Interest in the Study — 61 Participants
N/A N=59 A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA
Sexually Transmitted Infection · Hiv
Primary: Number of AGYW Who Tested Positive for a Sexually Transmitted Infection (STI) — 4; 6 Participants — p=0.15
Phase 2 N=80 Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Cerebral Cavernous Malformation
Primary: Percent Change in Mean Lesional QSM (QSM Change Score) — 7.35; 0.24; 15.18; 26.80 absolute value of percent change
N/A N=480 Impact of E-Cigarette Prevention Messages on Adolescents
Vaping Behavior
Primary: Mean Susceptibility to Vaping Score — 1.91; 1.82 score on a scale
N/A N=20 Prospective Randomized Endovascular Therapy in Multiple Sclerosis
Multiple Sclerosis
Primary: Percentage of Patients With Immediate and Short-term SAE — 0; 0 Participants
N/A N=320 Improving Women's Health Through Coordinated Postpartum Planning
Maternal Death · Maternal Morbidity
Primary: Number of Participants Attending a Comprehensive Postpartum Visit — 84; 89 Participants